慢性肺源性心脏病(Chronic Pulmonary Heart Disease, CPHD,简称为肺心病)是一种临床常见且与呼吸系统疾病密切相关的心脏疾病。主要是由于各种原因(如胸廓、支气管、肺组织或肺血管病变)致肺血管阻力增加,产生肺动脉高压,右心室后负荷...慢性肺源性心脏病(Chronic Pulmonary Heart Disease, CPHD,简称为肺心病)是一种临床常见且与呼吸系统疾病密切相关的心脏疾病。主要是由于各种原因(如胸廓、支气管、肺组织或肺血管病变)致肺血管阻力增加,产生肺动脉高压,右心室后负荷增大,导致其结构或(和)功能改变,其核心病理环节是肺动脉高压,其发病的病理基础是肺泡慢性缺氧,引起肺血管收缩、重构,血容量增多、血液黏稠度增加,最终肺动脉高压形成。CPHD已逐渐成为全世界关注的公共卫生问题,给患者生活质量和家庭带来了严重的负担。该病常反复发作,病死率高,是严重危害人类健康,影响人民幸福的疾病。故本文主要从西医发病机制、中医病因病机两方面来简述CPHD的研究概况。Chronic Pulmonary Heart Disease (CPHD) is a clinically common heart disease closely related to respiratory diseases. Mainly due to various reasons (such as chest, bronchus, lung tissue or pulmonary vascular diseases), pulmonary hypertension is caused by increased pulmonary vascular resistance, and the right ventricular afterload increases, resulting in changes in its structure or (and) function. The core pathological link is pulmonary hypertension, and its pathological basis is chronic alveolar hypoxia, which causes pulmonary vascular contraction and remodeling. Blood volume increases, blood viscosity increases, and eventually pulmonary hypertension develops. CPHD has gradually become a public health problem of worldwide concern, which brings serious burden to the quality of life of patients and families. The disease is often repeated, the fatality rate is high, is a serious harm to human health, affect people’s happiness of the disease. Therefore, this paper mainly summarizes the research situation of CPHD from two aspects: Pathogenesis of Western medicine and etiology and pathogenesis of Chinese medicine.展开更多
目的探讨罗格列酮辅助治疗对脓毒症肺损伤患者血清高迁移率族蛋白-1(high mobility group box1,HMGB1)、TNF-α及Th1/Th2影响研究。方法收集青海省中医院2013年8月~2014年8月收治的60例脓毒症肺损伤患者,按照用药方法随机分为实验组和...目的探讨罗格列酮辅助治疗对脓毒症肺损伤患者血清高迁移率族蛋白-1(high mobility group box1,HMGB1)、TNF-α及Th1/Th2影响研究。方法收集青海省中医院2013年8月~2014年8月收治的60例脓毒症肺损伤患者,按照用药方法随机分为实验组和对照组,各30例。对照组给予常规西医综合对症治疗,包括重症监护、胃肠减压、禁食水、补充血容量、抗炎、维持水和电解质平衡、改善微循环等。实验组在对照组治疗基础上给予患者罗格列酮,2次/天,2周为1个疗程,于1、3、7、14 d对所有患者的血清血清HMGB1、TNF-α及Th1/Th2进行检测。结果治疗后,与对照组相比,实验组患者各指标均显著改善,血清HMGB1水平降低显著(P<0.05);血清TNF-α水平降低较为显著(P<0.05);血清Th1/Th2比值降低显著(P<0.05)。结论罗格列酮辅助治疗能够显著降低HMGB1、TNF-α水平及Th1/Th2比值。展开更多
文摘慢性肺源性心脏病(Chronic Pulmonary Heart Disease, CPHD,简称为肺心病)是一种临床常见且与呼吸系统疾病密切相关的心脏疾病。主要是由于各种原因(如胸廓、支气管、肺组织或肺血管病变)致肺血管阻力增加,产生肺动脉高压,右心室后负荷增大,导致其结构或(和)功能改变,其核心病理环节是肺动脉高压,其发病的病理基础是肺泡慢性缺氧,引起肺血管收缩、重构,血容量增多、血液黏稠度增加,最终肺动脉高压形成。CPHD已逐渐成为全世界关注的公共卫生问题,给患者生活质量和家庭带来了严重的负担。该病常反复发作,病死率高,是严重危害人类健康,影响人民幸福的疾病。故本文主要从西医发病机制、中医病因病机两方面来简述CPHD的研究概况。Chronic Pulmonary Heart Disease (CPHD) is a clinically common heart disease closely related to respiratory diseases. Mainly due to various reasons (such as chest, bronchus, lung tissue or pulmonary vascular diseases), pulmonary hypertension is caused by increased pulmonary vascular resistance, and the right ventricular afterload increases, resulting in changes in its structure or (and) function. The core pathological link is pulmonary hypertension, and its pathological basis is chronic alveolar hypoxia, which causes pulmonary vascular contraction and remodeling. Blood volume increases, blood viscosity increases, and eventually pulmonary hypertension develops. CPHD has gradually become a public health problem of worldwide concern, which brings serious burden to the quality of life of patients and families. The disease is often repeated, the fatality rate is high, is a serious harm to human health, affect people’s happiness of the disease. Therefore, this paper mainly summarizes the research situation of CPHD from two aspects: Pathogenesis of Western medicine and etiology and pathogenesis of Chinese medicine.
文摘目的探讨罗格列酮辅助治疗对脓毒症肺损伤患者血清高迁移率族蛋白-1(high mobility group box1,HMGB1)、TNF-α及Th1/Th2影响研究。方法收集青海省中医院2013年8月~2014年8月收治的60例脓毒症肺损伤患者,按照用药方法随机分为实验组和对照组,各30例。对照组给予常规西医综合对症治疗,包括重症监护、胃肠减压、禁食水、补充血容量、抗炎、维持水和电解质平衡、改善微循环等。实验组在对照组治疗基础上给予患者罗格列酮,2次/天,2周为1个疗程,于1、3、7、14 d对所有患者的血清血清HMGB1、TNF-α及Th1/Th2进行检测。结果治疗后,与对照组相比,实验组患者各指标均显著改善,血清HMGB1水平降低显著(P<0.05);血清TNF-α水平降低较为显著(P<0.05);血清Th1/Th2比值降低显著(P<0.05)。结论罗格列酮辅助治疗能够显著降低HMGB1、TNF-α水平及Th1/Th2比值。
